SILO PHARMA, INC. Disposal Group, Including Discontinued Operation, Operating Income (Loss)
SILO PHARMA, INC. (SILO) reported Disposal Group, Including Discontinued Operation, Operating Income (Loss) of -$69.60 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss · last filed 2024-03-25
- SILO PHARMA, INC. disposal group, including discontinued operation, operating income (loss) for fiscal 2023 was -$69.60K.
- SILO PHARMA, INC. disposal group, including discontinued operation, operating income (loss) for fiscal 2022 was -$1.16K.
| Period end | Disposal Group, Including Discontinued Operation, Operating Income (Loss) 12 month |
|---|---|
| 2023-12-31 | -$69.60K 10-K · filed 2024-03-25 |
| 2022-12-31 | -$1.16K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |